ReviewBritish journal of cancer2022
Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Research on potential biomarkers of prostate cancer in Latin America and the Caribbean: a scoping review.Frontiers in oncology · 2026Pooled it
- Occupational Benzene Exposure and Risk of Male Genital Cancers: A Systematic Review and Meta-Analysis.American journal of industrial medicine · 2025Pooled it
- Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.Nature communications · 2023Pooled it
- Clinicopathological Profile of Prostate Cancer Patients at a Tertiary Hospital in the Eastern Cape, South Africa.International journal of environmental research and public health · 2026Article
- The effect of opium consumption on prostate cancer among Iranian patients: A retrospective analytical study.Medicine · 2026Article
- DHODH links mitochondrial bioenergetics, one-carbon metabolism, and DNA repair to sustain aggressive prostate adenocarcinoma.Cell communication and signaling : CCS · 2026Article
- An Analytic Pipeline to Obtain Reliable Genetic Ancestry Estimates from Tumor-Derived RNA Sequencing Data.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Lifestyle-Related Factors and Dietary Components that Affect the Risk of Prostate Cancer in a Brazilian Study Group.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Demographic inaccuracies and biases in the depiction of patients by artificial intelligence text-to-image generators.NPJ digital medicine · 2025Article
- Cancer Research Funding in Africa.Communications medicine · 2025Article
- Discovery of lncRNA-Based ProsRISK Score in Serum as Potential Biomarkers for Improved Accuracy of Prostate Cancer Detection.Journal of cellular and molecular medicine · 2025Article
- Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.Cancer discovery · 2025Article
- Unveiling the functions of five recently characterized lncRNAs in cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana.Research and reports in urology · 2025Article
- Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.JMIR medical informatics · 2024Article
- Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa.Nature genetics · 2024Article
- West African Genetic Ancestry, Neighborhood Deprivation, and Prostate Cancer.JAMA network open · 2024Article
- Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Article
- Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common solid tumour in men worldwide and it is also the most common cancer affecting men of African descent. Prostate cancer incidence and mortality vary across regions and populations. Some of this is explained by a large heritable component of this disease. It has been established that men of African and African Caribbean ethnicity are predisposed to prostate cancer (PrCa) that can have an earlier onset and a more aggressive course, thereby leading to poorer outcomes for patients in this group. Literature searches were carried out using the PubMed, EMBASE and Cochrane Library databases to identify studies associated with PrCa risk and its association with ancestry, screening and management of PrCa. In order to be included, studies were required to be published in English in full-text form. An attractive approach is to identify high-risk groups and develop a targeted screening programme for them as the benefits of population-wide screening in PrCa using prostate-specific antigen (PSA) testing in general population screening have shown evidence of benefit; however, the harms are considered to weigh heavier because screening using PSA testing can lead to over-diagnosis and over-treatment. The aim of targeted screening of higher-risk groups identified by genetic risk stratification is to reduce over-diagnosis and treat those who are most likely to benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.